Cellectis S.A. (ALCLS.PA)
EUR 1.45
(4.01%)
EUR 1.45
(4.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 249.57 Million USD | 84.49% |
| 2022 | 135.27 Million USD | -7.09% |
| 2021 | 145.6 Million USD | -9.35% |
| 2020 | 160.62 Million USD | 43.42% |
| 2019 | 111.99 Million USD | 121.48% |
| 2018 | 50.56 Million USD | 7.64% |
| 2017 | 46.97 Million USD | -17.05% |
| 2016 | 56.63 Million USD | -33.11% |
| 2015 | 84.66 Million USD | -10.83% |
| 2014 | 94.95 Million USD | 153.46% |
| 2013 | 37.46 Million USD | 12.1% |
| 2012 | 33.41 Million USD | -64.77% |
| 2011 | 94.86 Million USD | 396.58% |
| 2010 | 19.1 Million USD | 5.44% |
| 2009 | 18.11 Million USD | 23.92% |
| 2008 | 14.62 Million USD | 41.54% |
| 2007 | 10.32 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 258.53 Million USD | -2.03% |
| 2024 Q1 | 263.89 Million USD | 5.74% |
| 2023 Q4 | 249.57 Million USD | 86.84% |
| 2023 Q2 | 131.11 Million USD | 0.15% |
| 2023 FY | 249.57 Million USD | 84.49% |
| 2023 Q3 | 133.57 Million USD | 1.88% |
| 2023 Q1 | 130.91 Million USD | -3.22% |
| 2022 Q3 | 133.96 Million USD | -4.56% |
| 2022 Q4 | 135.27 Million USD | 0.98% |
| 2022 FY | 135.27 Million USD | -7.09% |
| 2022 Q2 | 140.36 Million USD | -2.62% |
| 2022 Q1 | 144.13 Million USD | -1.01% |
| 2021 Q3 | 150.73 Million USD | -2.9% |
| 2021 Q4 | 145.6 Million USD | -3.41% |
| 2021 FY | 145.6 Million USD | -9.35% |
| 2021 Q1 | 152.96 Million USD | -4.77% |
| 2021 Q2 | 155.24 Million USD | 1.49% |
| 2020 Q3 | 158.74 Million USD | 24.37% |
| 2020 FY | 160.62 Million USD | 43.42% |
| 2020 Q4 | 160.62 Million USD | 1.18% |
| 2020 Q1 | 100.54 Million USD | -10.22% |
| 2020 Q2 | 127.63 Million USD | 26.94% |
| 2019 Q2 | 100.21 Million USD | 25.85% |
| 2019 Q4 | 111.99 Million USD | 13.47% |
| 2019 FY | 111.99 Million USD | 121.48% |
| 2019 Q3 | 98.7 Million USD | -1.51% |
| 2019 Q1 | 79.63 Million USD | 57.47% |
| 2018 Q1 | 47.31 Million USD | 0.71% |
| 2018 Q4 | 50.56 Million USD | 4.31% |
| 2018 Q3 | 48.47 Million USD | 7.04% |
| 2018 Q2 | 45.29 Million USD | -4.27% |
| 2018 FY | 50.56 Million USD | 7.64% |
| 2017 Q3 | 49.25 Million USD | -13.88% |
| 2017 Q2 | 57.19 Million USD | 4.97% |
| 2017 Q1 | 54.49 Million USD | -3.78% |
| 2017 FY | 46.97 Million USD | -17.05% |
| 2017 Q4 | 46.97 Million USD | -4.63% |
| 2016 FY | 56.63 Million USD | -33.11% |
| 2016 Q4 | 56.63 Million USD | -14.6% |
| 2016 Q2 | 73.81 Million USD | -5.21% |
| 2016 Q3 | 66.31 Million USD | -10.16% |
| 2016 Q1 | 77.87 Million USD | -8.03% |
| 2015 Q4 | 84.66 Million USD | 20.28% |
| 2015 FY | 84.66 Million USD | -10.83% |
| 2015 Q3 | 70.39 Million USD | -2.04% |
| 2015 Q2 | 71.85 Million USD | -80.47% |
| 2015 Q1 | 367.93 Million USD | 287.49% |
| 2014 Q1 | 35.17 Million USD | -6.12% |
| 2014 FY | 94.95 Million USD | 153.46% |
| 2014 Q4 | 94.95 Million USD | -3.65% |
| 2014 Q3 | 98.55 Million USD | 214.1% |
| 2014 Q2 | 31.37 Million USD | -10.79% |
| 2013 Q3 | 35.67 Million USD | 2.8% |
| 2013 Q4 | 37.46 Million USD | 5.01% |
| 2013 FY | 37.46 Million USD | 12.1% |
| 2013 Q2 | 34.7 Million USD | 1.54% |
| 2013 Q1 | 34.17 Million USD | 2.26% |
| 2012 FY | 33.41 Million USD | -64.77% |
| 2012 Q3 | 32.78 Million USD | 22.28% |
| 2012 Q4 | 33.41 Million USD | 1.93% |
| 2012 Q2 | 26.81 Million USD | 0.0% |
| 2011 Q4 | 94.86 Million USD | 0.0% |
| 2011 FY | 94.86 Million USD | 396.58% |
| 2010 Q4 | 19.1 Million USD | 0.0% |
| 2010 FY | 19.1 Million USD | 5.44% |
| 2010 Q2 | 12.63 Million USD | 0.0% |
| 2009 Q4 | 18.11 Million USD | 0.0% |
| 2009 Q2 | 15.83 Million USD | 0.0% |
| 2009 FY | 18.11 Million USD | 23.92% |
| 2008 FY | 14.62 Million USD | 41.54% |
| 2008 Q4 | 14.62 Million USD | 0.0% |
| 2007 FY | 10.32 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -3510.749% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -90.44% |
| Adocia SA | 31.87 Million EUR | -683.103% |
| Aelis Farma SA | 13.08 Million EUR | -1808.066% |
| Biophytis S.A. | 15.84 Million EUR | -1474.705% |
| Advicenne S.A. | 24.37 Million EUR | -923.813% |
| genOway Société anonyme | 14.45 Million EUR | -1626.026% |
| IntegraGen SA | 5.97 Million EUR | -4073.637% |
| Medesis Pharma S.A. | 6.42 Million EUR | -3783.72% |
| Neovacs S.A. | 3.71 Million EUR | -6623.24% |
| NFL Biosciences SA | 3.62 Million EUR | -6793.036% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -3579.771% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -7439.786% |
| Sensorion SA | 13.22 Million EUR | -1786.822% |
| Theranexus Société Anonyme | 5.01 Million EUR | -4875.391% |
| TME Pharma N.V. | 2.78 Million EUR | -8861.4% |
| Valbiotis SA | 13.7 Million EUR | -1720.652% |
| TheraVet SA | 1.48 Million EUR | -16706.477% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -1119.342% |
| DBV Technologies S.A. | 38.74 Million USD | -544.143% |
| Genfit S.A. | 105.92 Million EUR | -135.624% |
| GeNeuro SA | 20.13 Million EUR | -1139.207% |
| Innate Pharma S.A. | 132.29 Million EUR | -88.655% |
| Inventiva S.A. | 101.59 Million EUR | -145.662% |
| MaaT Pharma SA | 22.46 Million EUR | -1010.95% |
| MedinCell S.A. | 77.77 Million EUR | -220.914% |
| Nanobiotix S.A. | 95.74 Million EUR | -160.68% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -322.443% |
| Poxel S.A. | 53.9 Million EUR | -363.025% |
| GenSight Biologics S.A. | 34.72 Million EUR | -618.677% |
| Transgene SA | 26.51 Million EUR | -841.189% |
| Valneva SE | 341.14 Million EUR | 26.842% |